E-viri
PDF
Recenzirano
Odprti dostop
-
Widge, Alicia T; Rouphael, Nadine G; Jackson, Lisa A; Anderson, Evan J; Roberts, Paul C; Makhene, Mamodikoe; Chappell, James D; Denison, Mark R; Stevens, Laura J; Pruijssers, Andrea J; McDermott, Adrian B; Flach, Britta; Lin, Bob C; Doria-Rose, Nicole A; O’Dell, Sijy; Schmidt, Stephen D; Neuzil, Kathleen M; Bennett, Hamilton; Leav, Brett; Makowski, Mat; Albert, Jim; Cross, Kaitlyn; Edara, Venkata-Viswanadh; Floyd, Katharine; Suthar, Mehul S; Buchanan, Wendy; Luke, Catherine J; Ledgerwood, Julie E; Mascola, John R; Graham, Barney S; Beigel, John H
The New England journal of medicine, 01/2021, Letnik: 384, Številka: 1Journal Article
Thirty-four adults received two 100-μg injections of Moderna’s mRNA SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody titers were measured at day 119 — 90 days after the second injection. By three different assays, binding and neutralizing antibody titers declined slightly but remained elevated and higher than titers in convalescent plasma.
